Independent U.S. Market Research

Biotech Catalysts, Stock Hubs & U.S. Small/Mid-Cap Research

Merlintrader publishes independent educational research on U.S.-listed biotech and small- and mid-cap stocks, with daily market briefings, FDA and PDUFA tracking, catalyst calendars and dedicated company hubs across biotech, space, defense, AI, cannabis, energy and critical minerals.

SUNDAY EVENING WRAP — AUGUST 23, 2026

A 50% tariff on Canadian goods went live over the weekend, and Monday is the first price on it

U.S. cash markets were closed all weekend. Every equity and ETF figure below is Friday 21 August’s official close; bitcoin is the only live mark and is labelled as such. The weekend’s news is policy news, and it reaches equities for the first time when index futures reopen Sunday at 18:00 ET.

THE WEEKEND HEADLINE — U.S. TARIFFS ON CANADA
  • TARIFF LIVE — A 50% duty took effect at 12:01 a.m. ET on Saturday 22 August, covering roughly US$20 billion of Canadian goods on the U.S. Trade Representative’s estimate, about C$28 billion on Ottawa’s. Prime Minister Mark Carney suspended negotiations late Friday and recalled Canada’s negotiators minutes before the midnight deadline.TRADE
  • WHAT IS IN — Electronics is the largest covered category at over US$4 billion, then plastics at about US$3 billion, followed by wood and paper, dairy, alcohol and cement. Energy, potash, fish and certain critical minerals sit outside the measure, as does anything already carrying a separate national-security tariff, including steel, aluminium, copper, vehicles and parts, semiconductors and patented medicines.SCOPE
  • LEGAL BASIS — The duty rests on Section 338 of the Tariff Act of 1930, a power that has not previously been used to impose a tariff and that requires no prior investigation. There is no exemption for goods qualifying under USMCA. A challenge in the U.S. Court of International Trade is widely expected.LAW
  • THE CLOCK — Canada says it will match dollar for dollar from 8 September, on steel, dairy, appliances, agricultural equipment, pulp and paper and electronics; the detailed list has not been published. The Bank of Canada decides on 2 September, six days before those counter-measures are due. Ottawa puts about 56,000 jobs at stake; University of Calgary economist Trevor Tombe estimates around 90,000 if the tariffs hold.CALENDAR
FRIDAY’S CLOSE, AND THE WEEK BEHIND IT
  • $SPY 765.72 (+0.41% on the day, -1.37% on the week), $QQQ 713.44 (+0.35%, -2.41%), $DIA 532.22 (+0.89%, -0.85%), $IWM 299.96 (+0.77%, -1.68%). Friday repaired part of the damage; the week still closed lower across all four.INDEXES
  • $TLT 82.05 (-0.35%) — long duration kept losing ground into the weekend, which is the same pressure that hit growth multiples midweek.RATES
  • $URA 46.07 (+5.09%) led the selected groups, with $UEC +14.44%, $CCJ +7.24% and $LEU +5.75%. $XBI 165.73 (+1.44%) and $GLD 423.36 (+1.95%) also finished higher.GROUPS
  • $SMH -0.40% and $NVDA 214.72 (-0.98% on the day, -4.64% on the week) went the other way. Semiconductors were the weak side of Friday’s tape three sessions before Nvidia reports.SEMIS
  • BTC — Bitcoin was quoted at about $77,332 on a live Sunday 19:30 UTC snapshot. That is weekend price discovery on a market that never closed, not a read on Monday’s equity open.CRYPTO
BIOTECH — WHAT THE FILINGS ACTUALLY SAY
  • $RARE — Ultragenyx announced on 19 August that the FDA granted accelerated approval to GENGLYCOS (pariglasgene brecaparvovec-opnr), formerly DTX401, for glycogen storage disease type Ia in patients eight years and older. The decision landed three days before the 22 August action date still shown on several third-party FDA calendars. Source: Form 8-K, Item 8.01, filed 19 August 2026.APPROVED
  • $CAPR — The 22 August target action date for deramiocel has passed. As of Sunday evening there is no public FDA decision and no company Form 8-K later than 13 August. Shares closed Friday at $6.29, down 7.97% on the day and 5.41% on the week. Silence is neither an approval nor a rejection, and action dates are routinely resolved before, on or after the target.PENDING
EUROPE AND ENERGY POLICY
  • OIL LEVY — Germany, Italy, Austria, Poland, Portugal and Spain are drafting a request to put a windfall tax on oil company profits before EU finance ministers at next month’s informal meeting in Dublin. The letter has not been sent, EU tax measures require unanimity, and Germany is split between the finance ministry and the chancellery.EU
  • NUCLEAR — France authorised preparatory site works, not construction, for two new reactors at Gravelines. It sits alongside the uranium complex that led Friday’s U.S. tape.ENERGY
THE WEEK’S FIXED DATES
  • TUE AUG 25 — FDA action date for Ziihera (zanidatamab-hrii) combinations in first-line HER2-positive advanced or metastatic gastroesophageal adenocarcinoma. Primary read-through $JAZZ, partner sensitivity $ZYME. U.S. July new-home sales at 10:00 a.m. ET.FDA / DATA
  • WED AUG 26 — $NVDA reports fiscal Q2 after the close, against company guidance of about $91 billion in revenue.EARNINGS
  • THU 27 – SAT 29 — The Kansas City Fed’s Jackson Hole symposium, themed on financial innovation, payments and policy. Fed Chair Kevin Warsh delivers his first keynote as chair on Friday morning 28 August. GDP and PCE also land in the same stretch.FED / MACRO
  • SEP 2 / SEP 8 — Bank of Canada decision, then Canada’s counter-tariffs. Two dated events that keep the trade story alive past this week.TRADE
WHAT WE COULD NOT VERIFY

No FDA decision document on deramiocel was locatable on Sunday, and no negotiating text from the U.S.-Canada talks has been published, so each government’s account of the breakdown remains its own. The precise Jackson Hole speaking time is not final until the Kansas City Fed publishes its agenda. Nothing here is a recommendation to buy or sell any security.

Read the extended Daily BriefingWeekly Market Pulse

Biotech Catalyst Calendar 2026

Last updated: 22 July 2026

Merlintrader tracks upcoming biotech catalysts for U.S.-listed companies, including PDUFA dates, FDA decisions, clinical-trial readouts, advisory committee meetings and other regulatory milestones. Alongside each date you will find the source, company context and the key risks that can move the stock, plus links to deeper Merlintrader research when it is available. The focus is educational and risk-aware, with particular attention to small and mid-cap biotech names, where catalyst timing, cash runway and dilution risk can drive sharp moves in volatility. Dates can change and FDA decisions can arrive early or late, so always confirm an event against company filings and regulatory sources before acting on it.

Listed / exchange-traded biotech focus

Weekly Biotech Catalyst Tracker

Window covered: August 22 → September 30, 2026. Compact homepage board for unresolved FDA decisions, regulatory submissions and major clinical readouts. A prior-date item remains visible only when the regulatory process is still materially open; catalysts resolved in the past few days are retained briefly for continuity. October and later events are excluded from this widget.

28On board
16FDA / Reg
12Data / Filing
Aug 22Updated
FDA / PDUFA Clinical data Filing watch High risk Large cap
$NRXP KETAFREE Ongoing FDA review First-cycle review complete; manufacturer vial attestation submitted

NRx Pharmaceuticals. The July 29 GDUFA goal date has passed, but the ANDA remains active. On August 7, NRx reported that FDA completed its first-cycle review of the preservative-free intravenous ketamine ANDA with no major deficiencies related to the drug product, ingredients, proposed labeling, CMC or other drug-related review matters. The sole remaining major deficiency involved the container-closure system and a manufacturer attestation concerning the luer-lock vial. The same vial is used in three approved ANDA products that collectively shipped 11.9 million units in the United States over the prior 12 months, while the KETAFREE filing included testing of more than 3,500 vials from seven manufactured lots without observed luer-lock failures. On August 17, NRx confirmed that the requested manufacturer attestation had been submitted to FDA. No new exact action date has been disclosed.

$REGN Pasatru Aug 19 Approved Second FDA-approved treatment for FOP

Regeneron. On August 19, 2026 the FDA approved Pasatru (garetosmab-grts) to reduce the formation of new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva, closing the August decision window the company had guided to without naming a day. Approval was based on the Phase 3 OPTIMA trial, which showed a 90 to 94 per cent reduction in new heterotopic ossification lesions and a decrease in flare-ups at 56 weeks. Pasatru is a fully human monoclonal antibody directed against activin A. The recommended starting dose is 10 mg/kg infused intravenously over 60 minutes once every four weeks, reducible to 3 mg/kg where the higher dose is not tolerated, and it can be administered across a range of care settings including home infusion. FDA describes it as the second approved treatment for FOP.

$CAPR deramiocel Aug 22* Extension expected BLA remains active; new 24-month data amendment planned

Capricor. The resubmitted deramiocel BLA remains under FDA review following the July 29 advisory committee vote of 9–3 against the sufficiency of the efficacy evidence for DMD-associated cardiomyopathy. Capricor subsequently said it plans to submit a BLA amendment incorporating 24-month HOPE-3 open-label-extension data and additional analyses focused on upper-limb function. The company has said FDA is willing to review the new information and that the August 22 deadline will be extended after the amendment is received. Until FDA or Capricor formally announces the revised action date, August 22 remains the last published PDUFA date but should no longer be treated as a fixed final-decision deadline.

$RARE GENGLYCOS Aug 19 Approved Accelerated approval four days ahead of the August 23 PDUFA

Ultragenyx. On August 19, 2026 the FDA granted accelerated approval to GENGLYCOS (pariglasgene brecaparvovec-opnr), previously known as DTX401, in adults and children aged eight years and older with glycogen storage disease type Ia. The decision landed four days before the August 23 PDUFA goal date the company had reaffirmed on August 4. The approved indication is narrower than the disease itself: the FDA label (STN 125858) covers the reduction of daily cornstarch intake as an adjunct to nutritional management, and continued approval may depend on verification of clinical benefit in confirmatory trials. The therapy can only be given to patients with no detectable anti-AAV8 antibodies, and the label carries warnings for hypersensitivity and infusion reactions, adrenal insufficiency and a theoretical risk of tumorigenicity from vector DNA integration. Approval rests on the 48-week randomised, double-blind, placebo-controlled Phase 3 GlucoGene study, which treated 46 participants and showed a statistically significant reduction in daily raw cornstarch requirements; the modified intention-to-treat population comprised 44 participants, 20 on DTX401 and 24 on placebo. It is the first gene therapy approval in the company history and its fifth FDA approval overall, and it carried a Priority Review Voucher.

$JAZZ Ziihera combo Aug 25 sBLA First-line HER2-positive GEA

Jazz Pharmaceuticals. Priority Review PDUFA for the Ziihera (zanidatamab-hrii) sBLA in combination with chemotherapy, with or without tislelizumab, for first-line locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma.

$GILD BIC/LEN Aug 27 NDA Once-daily oral HIV regimen

Gilead. Priority Review PDUFA for the bictegravir 75 mg/lenacapavir 50 mg NDA, a once-daily single-tablet regimen for virologically suppressed adults with HIV. This is a strategic lifecycle catalyst for the HIV franchise.

$PTGX rusfertide Q3 NDA Priority Review in polycythemia vera

Protagonist / Takeda. The rusfertide NDA in polycythemia vera is under Priority Review and no decision has been announced as of August 21. The joint Takeda and Protagonist announcement of the FDA filing acceptance, dated March 2, 2026, places the PDUFA goal date in the third quarter of 2026 without naming a month or a day, so the board shows the quarter rather than August. Rusfertide also holds Breakthrough Therapy, Orphan Drug and Fast Track designations. The submission rests on the Phase 3 VERIFY study together with the Phase 2 REVIEW study and the THRIVE long-term extension.

$TLX Pixclara Sep 11 PDUFA FDA decision on the resubmitted Pixclara NDA

Telix Pharmaceuticals. September 11, 2026 is the FDA PDUFA goal date for the resubmitted Pixclara (TLX101-Px) NDA. The application has already been submitted and accepted for review; the September catalyst is therefore the FDA decision on that NDA, not the NDA filing itself. Pixclara is a PET imaging agent intended to help characterize suspected recurrent or progressive glioma versus treatment-related changes.

$RARE UX111 Sep 19 BLA Gene therapy for Sanfilippo syndrome type A

Ultragenyx. PDUFA for the resubmitted UX111 (rebisufligene etisparvovec) BLA in Sanfilippo syndrome type A. The company reaffirmed September 19 in its August 4 update; the application seeks accelerated approval.

$MRK WINREVAIR Sep 21 sBLA PAH · HYPERION-based label update

Merck. PDUFA for an sBLA seeking a U.S. label update for WINREVAIR (sotatercept-csrk) based on the Phase 3 HYPERION study in pulmonary arterial hypertension. Merck reaffirmed the September 21 date with its second-quarter results.

$IONS zilganersen Sep 22 NDA Alexander disease

Ionis. Priority Review PDUFA for the zilganersen NDA in Alexander disease, a rare progressive neurological disorder. It remains one of September’s most closely watched rare-disease regulatory catalysts.

$GRAL Galleri Sep 23 FDA panel AdCom on the multi-cancer MCED test PMA

GRAIL. FDA’s Molecular and Clinical Genetics Panel will meet on September 23 to discuss and vote on the Galleri premarket approval application. Galleri is a blood-based multi-cancer early detection test proposed for screening adults aged 50 and older. This is not a drug PDUFA; it is a device and diagnostics regulatory catalyst that is nevertheless material to the stock.

$MIRM zilurgisertib Sep 26 NDA FOP · patients aged 12 and older

Mirum Pharmaceuticals / Incyte. Priority Review PDUFA for the zilurgisertib NDA in fibrodysplasia ossificans progressiva in patients aged 12 years and older. Mirum holds exclusive worldwide rights under license from Incyte.

$BFRI Ameluz PDT Sep 28 sNDA Expansion into superficial BCC

Biofrontera. PDUFA for the Ameluz photodynamic-therapy sNDA in superficial basal cell carcinoma. FDA completed its filing review without identifying filing deficiencies and assigned September 28 as the target action date.

$SRRK apitegromab Sep 30 BLA SMA · review continues with second fill-finish site

Scholar Rock. The apitegromab BLA in spinal muscular atrophy remains targeted to September 30. On August 7, the company said that, in coordination with FDA, Catalent Indiana is being removed from the BLA and review is continuing using the second fill-finish facility; the related data package is under review. CMC and manufacturing risk therefore remain central, while the company continues to state that the action date is unchanged.

$ROIV brepocitinib Q3 NDA Dermatomyositis · Priority Review

Priovant / Roivant. The brepocitinib NDA in dermatomyositis is under Priority Review. The company has disclosed a PDUFA target action date in the third quarter of 2026 and, if approved, has pointed to a possible U.S. launch around the end of September. No exact PDUFA day has been made public.

$QURE AMT-130 Q3 BLA Accelerated-approval BLA filing in Huntington’s disease

uniQure. The company is preparing an AMT-130 BLA in Huntington’s disease after alignment with FDA on a pathway that may use comparison with an external control as the primary basis of the application. The submission remains a Q3 2026 catalyst; it is not a PDUFA, and FDA filing acceptance would be the next formal step.

$IMMX NXC-201 Late Sep Data NEXICART-2 · AL amyloidosis

Immix Biopharma. The next NEXICART-2 update for NXC-201 in relapsed or refractory AL amyloidosis is expected in late September 2026. The program is designed as BLA-enabling/registrational, and subsequent follow-up is expected to contribute to the regulatory path.

$KPTI selinexor combo Aug sNDA Selinexor + ruxolitinib filing in myelofibrosis

Karyopharm. The former XPORT-EC-042 endometrial-cancer catalyst is resolved: on July 30, the study did not meet its primary progression-free-survival endpoint. The active event is now the sNDA the company plans to submit in August for selinexor combined with ruxolitinib in myelofibrosis, with a request for Priority Review.

$KOD DAYBREAK Sep Phase 3 Wet AMD · Zenkuda and KSI-501

Kodiak Sciences. One-year primary-endpoint topline results from the Phase 3 DAYBREAK study in wet age-related macular degeneration are expected in September 2026. The study evaluates Zenkuda (tarcocimab tedromer) and KSI-501 in parallel against aflibercept.

$ALMS envudeucitinib Q3 Data LUMUS Phase 2b in SLE

Alumis. Phase 2b LUMUS results for envudeucitinib in systemic lupus erythematosus are expected in the third quarter. For an autoimmune readout, the market will assess not only statistical significance but also dose consistency, clinical endpoints and the safety profile.

$IVVD VYD2311 Late Q3 Data DECLARATION pivotal study

Invivyd. Topline data from the pivotal DECLARATION study of VYD2311 are expected approximately toward the end of the third quarter of 2026. The timing remains company guidance rather than a calendar-specific date.

$PHVS deucrictibant XR Q3 Phase 3 CHAPTER-3 · HAE prophylaxis

Pharvaris. Phase 3 CHAPTER-3 topline data for extended-release deucrictibant in hereditary-angioedema prophylaxis remain expected in the third quarter of 2026. This is one of the quarter’s most important registrational HAE readouts.

$SYRE SPY003 Sep Data SKYLINE Phase 2 in ulcerative colitis

Spyre Therapeutics. SPY003 Part A topline data from the Phase 2 SKYLINE study are expected in September 2026. The company has now specified September rather than only the broader third-quarter window; no exact day has been disclosed.

$VERA TRUTAKNA / atacicept Q3 eGFR ORIGIN 3 confirmatory follow-up

Vera Therapeutics. The ORIGIN 3 eGFR analysis is expected in the third quarter following accelerated approval of atacicept. This is not another approval decision; its significance lies in the durability of the renal effect and the read-through for the confirmatory pathway.

$XENE azetukalner Q3 NDA Focal-onset seizure filing

Xenon. The azetukalner NDA submission in focal-onset seizures remains on track for the third quarter. Filing confirmation would begin FDA’s filing-review stage and set up a later PDUFA assignment.

$BBIO infigratinib Aug 10 NDA submitted Achondroplasia · FDA filing acceptance now becomes the next step

BridgeBio. BridgeBio confirmed on August 10, 2026 that it had submitted the NDA for oral infigratinib in achondroplasia to FDA. The former Q3 “submission” catalyst has therefore occurred. The program remains on the board because the regulatory process is materially open: FDA filing acceptance and any subsequent PDUFA assignment are now the next formal milestones. Infigratinib has Breakthrough Therapy, Fast Track and Rare Pediatric Disease designations in the United States.

$MLTX sonelokimab Late Sep BLA Hidradenitis suppurativa filing

MoonLake. The sonelokimab BLA submission in hidradenitis suppurativa is expected around the end of September 2026. FDA filing acceptance would create the next formal regulatory event.

Most attention-worthy watchlist

$NRXP $CAPR $RARE $PTGX $IONS $GRAL $MIRM $SRRK $PHVS $QURE $IMMX

Board rule

Only future or still materially unresolved catalysts through September are shown; catalysts resolved in the past few days are retained briefly for continuity. Two FDA approvals landed on August 19 and both stay on the board for now: $RARE/GENGLYCOS, cleared four days ahead of its August 23 PDUFA, and $REGN/Pasatru, which closed the August decision window Regeneron had guided to without naming a day. $AMLX/LUCIDITY has rolled off after one update; the August 18 Phase 3 readout was positive on the primary endpoint and on all secondary endpoints, and Amylyx still guides to an NDA by the end of 2026. $EYPT/LUGANO has been removed after EyePoint reported the readout on August 17; the full dataset did not meet the primary BCVA noninferiority endpoint, although an ad hoc analysis excluding nine patients supported noninferiority and several secondary measures were favorable. $TENX/LEVEL has been removed after the August 10 Phase 3 readout failed both the primary 6MWD endpoint and the key KCCQ-TSS secondary endpoint. $SLN/SANRECO has been removed after the August 10 positive Phase 2 results. $BMY/iberdomide has been removed after FDA granted accelerated approval to ZENBEXUS on August 13. $LNTH/TAUKLARIFY, approved on August 14, has also rolled off the board. $CLNN has been removed because Clene moved the planned CNM-Au8 ALS NDA submission to early Q4 2026, outside this widget. $NRXP remains because the requested manufacturer vial attestation has now been submitted to FDA but no new exact action date has been disclosed. $CAPR remains because the BLA review is still open. The August 22 date falls tomorrow and no revised action date has been announced as of August 21; the most recent company statement on the planned 24-month HOPE-3 amendment is the August 13 second-quarter update, in which Capricor said FDA had indicated it was willing to review the amendment and to extend the action date once it is received. $BBIO remains because the infigratinib NDA was submitted on August 10 and filing acceptance is now the next formal regulatory milestone. For $SYRE, company guidance now specifies September 2026 for SPY003. $PTGX moves from August to Q3 because the only primary-source statement on the rusfertide goal date, the March 2 filing-acceptance announcement, says third quarter of 2026 and names neither a month nor a day. $KPTI stays on an August window: as of its August 13 second-quarter update Karyopharm was on track to submit the selinexor plus ruxolitinib sNDA during August with a request for Priority Review, and no announcement confirming the submission has been found. Month-only and quarter-only windows reflect disclosed guidance and are not exact FDA dates.

Educational content only — not investment advice or a recommendation to buy or sell securities. Verify dates and primary filings before trading around binary events. Full catalyst calendar FDA SEC EDGAR

Biotech Catalyst Lookup

Type a ticker to get an AI-generated snapshot of the next catalyst (PDUFA, clinical data, regulatory events) with a link to the primary source.

Disclaimer. This content is for educational and informational purposes only. It is not investment advice and not a recommendation to buy or sell any security, in line with SEC (USA) guidance. Data is generated by AI from web sources and may contain errors or be out of date — always verify against the linked primary source. Do your own research and consult a licensed advisor. Full disclaimer: merlintrader.com/disclaimer.